Eczema, or atopic dermatitis, often worsens during seasonal changes like monsoon and autumn. Fluctuating humidity, allergens, ...

If you or someone you love has eczema, you know treating it can be frustrating. It takes a lot of trial and error to f ...

Shares in French drugmaker Sanofi ($SNY) sickened today as trial data on a new eczema treatment disappointed investors. Met ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Eczema can be very distressing for children – and now it seems that its roots may at least partly lie in their mothers ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 9% on Thursday after the drugmaker reported results from a large trial of its experimental eczema treatment amlitelimab that showed weaker ...

Amlitelimab study met its goals but results were not meaningfully better than Dupixent ...

The Health Canada approval is based on the results from the DELTA 1 and 2 clinical trials, which included 960 adult patients with moderate to severe CHE (20 per cent of which were Canadian). 2,3 Both ...

Anyone can have eczema, though CDC data shows that it’s disproportionately diagnosed in women. This complex condition is strongly linked to allergies, asthma, and other autoimmune issues. Common ...

The Cutera Laser Genesis has been shown to help minimize broken capillaries, large pores, fine lines and some scarring, but ...

Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding ...